Duos Technologies Group (DUOT) Stock Price Faces Earnings Quality Scrutiny

Duos Technologies Group stock slipped 3.3% to US$10.40 today, even though the headline numbers looked anything but weak. Q2 delivered a sharp swing into profit with basic earnings per share of US$1.61 and net income from continuing operations in the trailing twelve months of US$38.22m. The real story for you is not today’s red print on the screen. It is a freshly reshaped AI infrastructure business now reporting positive earnings and carrying a P/E of 8.5x, which sits well below the broader US software sector.

Is Duos Technologies Group trading at a genuine discount with an 8.5x P/E, or just screening as cheap because of non cash earnings and recent dilution? Compare the stock’s reported multiples against fundamentals on our valuation analysis for Duos Technologies Group.
Advertisement

Q2 2026 Earnings Summary

  • Revenue (Q2 2026 vs Q2 2025): US$6.18m vs. US$5.74m (up about 8%)
  • Net Income from Continuing Operations (Q2 2026 vs Q2 2025): US$48.66m profit vs. US$3.52m loss (a large swing into profit, heavily influenced by non cash items and asset sales)
  • Basic EPS (Q2 2026 vs Q2 2025): US$1.61 vs. a loss of US$0.30 per share (a large swing into positive EPS, helped by one off non cash gains)
  • Gross Margin (Q2 2026): 55.8% for Q2 2026 (reflects a higher margin AI infrastructure and technology mix for Duos Technologies Group)

Prefer clean visual charts over long walls of earnings text and raw figures? See Duos Technologies Group’s full financial picture, including a clear view of its valuation, all laid out in an easy dashboard through our company report for Duos Technologies Group.

NasdaqCM:DUOT Trailing 12-Month Earnings & Revenue History as at Aug 2026
NasdaqCM:DUOT Trailing 12-Month Earnings & Revenue History as at Aug 2026

Duos Technologies Group bull case gets first real test

The bullish story says Duos Technologies Group has completed its shift into a funded AI infrastructure platform with real recurring revenue momentum, not just a one off gain. Q2 gives some backing to that view. Continuing operations revenue of US$6.18m now comes mainly from AI focused Technology Solutions at US$3.23m and higher margin infrastructure work, with a 55.8% gross margin that fits the promised mix shift. Adjusted EBITDA turned positive at about US$0.5m and operating income was slightly positive, which matters for a capital intensive build out. Bookings of roughly US$43.5m expected in 2026 and about US$25m of Technology Solutions backlog show customers committing real dollars to the edge data center plan. A cash balance of US$112.3m and minimal debt gives Duos room to keep building pods without immediately leaning on new equity.

Bear case on quality of earnings not fully cleared

The bear story argues that Duos is leaning on short duration asset management revenue, one off APR gains and heavy spend while racing into a new business model. Q2 results do not erase those worries. The US$47.8m net income largely comes from an about US$53.2m gain on the APR stake, not from recurring operations. Related party and Asset Management Agreement revenue of US$2.91m still carries weight, helped by US$2.71m of accelerated deferred APR revenue that will not repeat. The APR agreement ends in 2026, so that stream will roll off. Capital intensity is clear, with US$68.8m of deposits into the GPU equipment program and a US$30m Columbus acquisition that includes a US$15m seller note. The share price reaction today, down 3.26%, suggests investors are still questioning how much of the current profitability is repeatable.

After such a heavy reliance on one off non cash gains and a volatile share price, you might want to stress test whether this is just the visible part of a larger risk profile. Review our full risk analysis for Duos Technologies Group which shows 4 important warning signs.

Stay Ahead Of Your Next Move

If Duos Technologies Group’s mix of AI infrastructure growth efforts and one off gains has your attention, register for free with Simply Wall St and add it to a Watchlist to watch how the share price tracks against fair value and decide on a potential entry point. Once you are invested, keep your focus with the Portfolio Command Center that filters market noise so you see only the most important updates on Duos Technologies Group and your other holdings. For a broader view, tap into the Community to see how other investors are interpreting the same earnings, risks and catalysts. By spotting hidden catalysts and emerging risks early, you give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond Duos Technologies Group?

Fresh stock ideas can move from quiet accumulation to full breakout before most investors react. Scan what is flying under the radar for now and consider your options promptly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

MI
mitchell_lawler
mitchell_lawler

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap. cover
168
PR
pri_dlp7z

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.

QU
Quantanium

There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.

Market might be getting a little ahead of itself here.

About NasdaqCM:DUOT

Duos Technologies Group

Designs, develops, deploys, and operates intelligent technology solutions in North America.

Excellent balance sheet with slight risk.

Advertisement

Weekly Picks

RI
Rick_Orford
FJET logo
Rick_Orford on Starfighters Space ·

The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market

Fair Value:US$520.4% undervalued
55 users have followed this narrative
3 users have commented on this narrative
7 users have liked this narrative
JO
John_Eric
MELI logo
John_Eric on MercadoLibre ·

MercadoLibre and the Spreadsheet Trick That Decides Everything

Fair Value:US$7.31k73.7% undervalued
100 users have followed this narrative
2 users have commented on this narrative
16 users have liked this narrative
RC
PYPL logo
rcb9 on PayPal Holdings ·

Ten Percent More Volume, One Percent More Transaction Margin

Fair Value:US$70.8912.1% undervalued
14 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative
HE
HedgeY
MU logo
HedgeY on Micron Technology ·

Micron - The Memory Bottleneck Behind the AI Supercycle

Fair Value:US$1.25k22.1% undervalued
39 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative

Updated Narratives

HA
HarishPK
EVER logo
HarishPK on EverQuote ·

EverQuote and an Asymmetric Investment Opportunity

Fair Value:US$3834.1% undervalued
1 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
RI
7974 logo
richard_53rym on Nintendo ·

Nintendo facing the Ram shortage situation

Fair Value:JP¥9.62k8.7% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RI
richard_khp08
CIGN logo
richard_khp08 on Cigna Group ·

Cigna Group (CI) : la machine à cash-flow mal-aimée du secteur de la santé

Fair Value:€29219.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.6% undervalued
332 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9114.6% overvalued
185 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0945.3% undervalued
211 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative

Trending Discussion

MA
MRNA logo
Madave on Moderna ·

Aged like wine

1
|
0
ZD
Zdend1
FDC logo
Zdend1 on FDC Consolidated Holdings ·

A well thought out narrative! Keep me updated.

1
|
0